Key result
Single oral and intravenous doses of propafenone significantly prolonged ECG intervals, with the metabolite 5-hydroxy-propafenone showing an additive effect on QRS duration in 7 of 8 subjects.
Why the study?
Does oral propafenone compared to intravenous propafenone have different pharmacodynamic effects on ECG intervals in healthy extensive metabolizers?
Population
8 healthy extensive metabolizers
Comparison
Single oral dose of propafenone (300 to 450 mg) vs Single intravenous dose of propafenone
Design
RCT, randomized, single-blind
Authors
Loading...
Oral propafenone ECG effects include active metabolite contribution; extends pharmacodynamic data and supports metabolite-aware dosing in extensive metabolizers.
RCT (n=8)
Single-blind
randomized
Does oral propafenone compared to intravenous propafenone have different pharmacodynamic effects on ECG intervals in healthy extensive metabolizers?
The major metabolite 5-hydroxy-propafenone exerts pharmacologic activity on ECG intervals and may contribute to the antiarrhythmic effect of oral propafenone.
Haefeli et al. (1990) conducted an RCT in healthy extensive metabolizers (n=8). Propafenone vs. Intravenous vs oral administration was evaluated on ECG intervals (PQ interval and QRS duration). Single oral and intravenous doses of propafenone significantly prolonged ECG intervals, with the metabolite 5-hydroxy-propafenone showing an additive effect on QRS duration in 7 of 8 subjects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: